Free Trial

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 3.6% - What's Next?

Recursion Pharmaceuticals logo with Medical background

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price was up 3.6% on Wednesday . The stock traded as high as $7.34 and last traded at $7.24. Approximately 13,659,767 shares traded hands during trading, an increase of 100% from the average daily volume of 6,818,902 shares. The stock had previously closed at $6.99.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on RXRX shares. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group dropped their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $9.25.

View Our Latest Stock Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock Up 3.6 %

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a fifty day simple moving average of $6.77 and a 200-day simple moving average of $7.16. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -4.73 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter in the prior year, the business posted ($0.43) EPS. The business's quarterly revenue was up 147.6% compared to the same quarter last year. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity

In related news, CFO Michael Secora sold 15,000 shares of the firm's stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the business's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company's stock, valued at $3,647,966. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,788 shares of company stock valued at $724,691. 15.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC lifted its position in Recursion Pharmaceuticals by 16.4% during the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company's stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the period. State Street Corp increased its stake in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company's stock valued at $84,815,000 after buying an additional 4,120,685 shares during the period. FMR LLC raised its holdings in Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company's stock valued at $55,116,000 after buying an additional 170,810 shares during the last quarter. Geode Capital Management LLC grew its holdings in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock worth $35,803,000 after acquiring an additional 656,003 shares during the last quarter. Finally, Lingotto Investment Management LLP increased its position in Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company's stock valued at $27,563,000 after acquiring an additional 1,500,000 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Further Reading

Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?

Before you consider Recursion Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.

While Recursion Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines